Welcome to our dedicated page for Amneal Pharmaceuticals news (Ticker: AMRX), a resource for investors and traders seeking the latest updates and insights on Amneal Pharmaceuticals stock.
Amneal Pharmaceuticals Inc (NYSE: AMRX) delivers essential medicines through its focus on affordable generics and specialty pharmaceuticals. This news hub provides investors and healthcare professionals with timely updates on regulatory developments, strategic partnerships, and operational milestones.
Our curated collection features official press releases and verified news coverage spanning key business segments. Track updates on generic drug approvals, manufacturing expansions, and AvKARE distribution network enhancements. Access filings related to FDA submissions, intellectual property developments, and corporate governance matters.
Discover comprehensive coverage of earnings announcements, research collaborations, and therapeutic area advancements. The resource serves as an objective reference for monitoring AMRX's role in improving medication accessibility while maintaining quality standards across global markets.
Bookmark this page for streamlined access to Amneal's latest developments in generic pharmaceuticals and complex drug formulations. Regularly updated content supports informed analysis of this NYSE-listed company's market position and industry contributions.
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) will participate in three upcoming investor conferences. The Jefferies London Healthcare Conference is scheduled for November 18, 2021. The Goldman Sachs Global Sustainability Forum will take place on November 30, 2021. Additionally, Amneal will present at the Evercore ISI 4th Annual HEALTHCONx Virtual Conference on December 1, 2021, with a presentation starting at 8:25 AM Eastern Time. A live webcast will be available on the company's Investor Relations website.
Amneal Pharmaceuticals (NYSE: AMRX) reported Q3 2021 net revenue of $529 million, a 2% increase year-over-year, driven by new generic launches and growth in specialty products like Rytary® and Unithroid®. The company posted a net loss of $(4) million compared to $(9) million in Q3 2020, reflecting improved gross margins and decreased impairment charges. Adjusted EBITDA rose to $135 million, up 19% from last year. Amneal also announced the acquisition of Puniska Healthcare for $93 million, enhancing its injectables capabilities and expanding market reach.
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) has released its inaugural Corporate Responsibility Report, showcasing its commitment to environmental, social, and governance (ESG) practices with data primarily from 2020 and highlights from 2021. The report details Amneal's focus on five key impact areas: people, products, governance, planet, and community, including its role in combating COVID-19. The company emphasizes its ongoing dedication to enhancing employee diversity, R&D for affordable medications, and supporting social advocacy.
Amneal Pharmaceuticals (NYSE: AMRX) has announced the launch of dexamethasone in 4mg and 6mg formulations following FDA approval. This glucocorticoid steroid is crucial for treating various conditions, including COVID-19 complications. The U.S. market for these dexamethasone tablets reached approximately $63 million in annual sales as of August 2021. The company emphasizes its commitment to expanding access to essential therapies while recognizing potential risks, including HPA axis suppression and contraindications for allergic patients.
Amneal Pharmaceuticals (NYSE: AMRX) will release its Q3 2021 financial results on November 3, 2021, before market open. A conference call and live webcast will follow at 8:30 a.m. ET on the same day. Investors can access the results and webcast via the Investor Relations section of the company's website. Callers in the U.S. can reach the conference at (844) 200-6205, while international callers can dial (929) 526-1599. A replay will be available for seven days using access code 781882.
Amneal Pharmaceuticals (NYSE: AMRX) announced its participation in the Morgan Stanley Global Healthcare Conference on September 15, 2021, at 1:15 PM ET. Investors can access the live webcast through the company's Investor Relations page, with a replay available for 90 days afterward. Amneal is a fully-integrated pharmaceutical company based in Bridgewater, NJ, focusing on generic and specialty drug products, with a portfolio of approximately 250 product families.
Amneal Pharmaceuticals (NYSE: AMRX) announced positive topline results from its pivotal Phase 3 RISE-PD clinical trial for IPX-203, a novel formulation for Parkinson’s disease. The trial met its primary endpoint, showing an increase of 0.53 hours in “Good On” time compared to immediate-release CD/LD (p=0.0194). A New Drug Application submission to the FDA is planned for mid-2022. The trial involved 506 patients across 108 sites, demonstrating the drug's efficacy and safety, with 29.7% of patients reporting significant improvements (p=0.0015).
Amneal Pharmaceuticals (NYSE: AMRX) will host a virtual investment event on August 25, 2021, at 4:30 p.m. ET. The event will include presentations from management and medical experts. Key focus will be on IPX-203, an investigational oral formulation of extended-release CD/LD for Parkinson's patients, designed to improve absorption. Unlike RYTARY, IPX-203 uses innovative mucoadhesive polymers for rapid absorption. Amneal aims to enhance its portfolio with complex dosage forms and marketed brands, primarily in the CNS and endocrine disorders.
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) reported strong second quarter results for 2021, achieving net revenues of $535 million, a 15% increase from $465 million in Q2 2020. The growth was attributed to successful Generic product launches and an uptick in Specialty products like Rytary® and Unithroid®. Notably, net income rose to $15 million, compared to a net loss of $12 million the previous year, driven by improved gross margins in Generics. Adjusted EBITDA also surged by 50% to $151 million. The company maintains its 2021 outlook for revenue between $2.1 and $2.2 billion.
Amneal Pharmaceuticals (NYSE: AMRX) has received FDA approval for its generic version of TobraDex®, Dexamethasone and Tobramycin Ophthalmic Suspension 0.3%/0.1%. This addition strengthens its generics portfolio, focusing on complex ophthalmic products. TobraDex® is used for steroid-responsive inflammatory ocular conditions and had U.S. sales of approximately $118 million for the year ending May 2021. The approval underscores Amneal's strategy to develop complex generics, enhancing its market position.